EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case–Control Study

Laura Serrano-Aguilar, Cristina Fernandez-Hombrados, Mercedes Jimenez-Vargas, Yolanda López-Moreno iD, Guillermina García-Martín iD, Pablo Cabezudo-García iD, Nicolas Lundahl Ciano-Petersen iD, Guillermo Estivill-Torrús iD, Manuel Narváez-Peláez iD, Maria José Aguilar-Castillo iD, Virgilio Hernándo-Requejo, Pedro Jesus Serrano-Castro iD

Biomolecules · 2026

DOI: 10.3390/biom16091350 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Biomolecules, 2026. Verfasst von Laura Serrano-Aguilar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, San Pablo CEU University, Av. de Montepríncipe, 28668 Alcorcón, Spain. Hauptthemen laut MEDLINE: Biomarkers, Epilepsy, Autoimmune Diseases. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Progreso y Salud, Andalusian Network of Clinical and Translational Research in Neurology, Alianza Andalucía-Roche de Neurología Médica de Precisión.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autoimmune-associated epilepsy (AAE) was recognized by the ILAE in 2017 as a distinct etiological category driven by chronic neuroinflammation rather than structural or genetic mechanisms. Reliable peripheral circulating inflammatory biomarkers to distinguish AAE from structural epilepsy remain lacking, potentially limiting timely recognition and evaluation for immunotherapy. In this observational case–control exploratory single-center study, plasma levels of 20 pro-inflammatory and 3 anti-inflammatory biomarkers, plus cerebrospinal fluid neurofilament light chain and HMGB1, were measured in 18 AAE patients, 33 non-autoimmune epilepsy patients and 16 healthy controls. AAE was defined using Dubey’s APE2-based criteria. Univariate comparisons, ROC analysis, and binary logistic regression were performed.

Results

Among the 25 biomarkers analyzed, plasma IL-12 showed the lowest nominal p-value in the global between-group comparison (p=0.038), with lower concentrations in AAE. However, no biomarker remained statistically significant after Benjamini–Hochberg false discovery rate correction (IL-12 q=0.366). ROC analysis yielded an AUC of 0.670 for IL-12 alone for distinguishing AAE from the remainder of the cohort. In an exploratory primary multivariable model including plasma IL-12, drug-resistant epilepsy (DRE) status, and EEG pattern, the apparent in-sample discriminative performance was higher than that of IL-12 alone (AUC = 0.771; 95% CI, 0.635–0.892).

Discussion

Lower plasma IL-12 levels may reflect a peripheral immune association in chronic AAE. These findings are exploratory and hypothesis-generating and require replication in larger, prospectively recruited, independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersEpilepsyAutoimmune DiseasesHumansFemaleMaleCase-Control StudiesAdultInterleukin-12Middle AgedROC CurveChronic DiseaseNeurofilament ProteinsInflammationHMGB1 Protein

Stichwörter der Autor:innen

IL-12autoimmune associated epilepsybiomarkersepilepsyneuroinflammation

Substanzen

BiomarkersInterleukin-12Neurofilament ProteinsHMGB1 Protein

Autor:innen und Institutionen

  • Faculty of Medicine, San Pablo CEU University, Av. de Montepríncipe, 28668 Alcorcón, Spain.
  • Neuroscience Unit, Neurology Service, University Regional Hospital of Málaga, 29010 Málaga, Spain.
  • Malaga Biomedical Research Institute and Nanomedicine Platform (IBIMA Plataform BIONAND), 29590 Málaga, Spain.
  • Red Andaluza de Investigación Clínica en Neurologia (Neuro-RECA), 29010 Málaga, Spain.
  • Department of Physiology, University of Malaga, 29010 Málaga, Spain.
  • Laboratory Service, Regional University Hospital of Málaga, 29010 Málaga, Spain.

ORCID-Profile: Yolanda López-Moreno, Guillermina García-Martín, Pablo Cabezudo-García, Nicolas Lundahl Ciano-Petersen, Guillermo Estivill-Torrús, Manuel Narváez-Peláez, Maria José Aguilar-Castillo, Pedro Jesus Serrano-Castro

Förderung

  • Fundación Progreso y Salud
  • Andalusian Network of Clinical and Translational Research in Neurology
  • Alianza Andalucía-Roche de Neurología Médica de Precisión
  • Progress and Health Foundation, Ministry of Health and Consumer Affairs of Andalusia

Zitieren

APA

Serrano-Aguilar, L., Fernandez-Hombrados, C., Jimenez-Vargas, M., López-Moreno, Y., García-Martín, G., Cabezudo-García, P., Ciano-Petersen, N. L., Estivill-Torrús, G., Narváez-Peláez, M., Aguilar-Castillo, M. J., Hernándo-Requejo, V., & Serrano-Castro, P. J. (2026). Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case–Control Study. Biomolecules. https://doi.org/10.3390/biom16091350

Vancouver

Serrano-Aguilar L, Fernandez-Hombrados C, Jimenez-Vargas M, López-Moreno Y, García-Martín G, Cabezudo-García P, et al. Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case–Control Study. Biomolecules. 2026. doi:10.3390/biom16091350

BibTeX
@article{SerranoAguilar2026,
  author = {Serrano-Aguilar, Laura and Fernandez-Hombrados, Cristina and Jimenez-Vargas, Mercedes and López-Moreno, Yolanda and García-Martín, Guillermina and Cabezudo-García, Pablo and Ciano-Petersen, Nicolas Lundahl and Estivill-Torrús, Guillermo and Narváez-Peláez, Manuel and Aguilar-Castillo, Maria José and Hernándo-Requejo, Virgilio and Serrano-Castro, Pedro Jesus},
  title = {Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case–Control Study},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16091350}
}
Kostenlos starten →